Ben Z Stanger
Overview
Explore the profile of Ben Z Stanger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
15095
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orlen M, Vostrejs W, Sor R, McDevitt J, Kemp S, Kim I, et al.
Cancer Discov
. 2025 Mar;
PMID: 40057911
Activating mutations in KRAS drive tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and contributing to an immunosuppressive tumor microenvironment (TME) rendering PDAC tumors insensitive to immunotherapy. RAS(ON)...
2.
Kowalewski K, Adair S, Talkington A, Wieder J, Pitarresi J, Perez-Vale K, et al.
bioRxiv
. 2025 Feb;
PMID: 39974981
One-sentence Summary: We show that hypoxic fibroblasts in pancreas cancer leverage histone methylation and ROS-mediated NF-κB activation to produce growth factors that drive epithelial-mesenchymal transition in malignant cells, demonstrating how...
3.
Gupta M, Choi H, Kemp S, Furth E, Pickup S, Clendenin C, et al.
bioRxiv
. 2024 Dec;
PMID: 39651222
Translational Relevance: Emerging small molecule KRAS inhibitors (KRASi) represent a new class of therapy for PDAC. Clinical tools that can provide biological insights beyond tumor size change are desirable for...
4.
Loveless I, Kemp S, Hartway K, Mitchell J, Wu Y, Zwernik S, et al.
Clin Cancer Res
. 2024 Dec;
31(4):756-772.
PMID: 39636224
Purpose: Pancreatic ductal adenocarcinoma (PDAC) patients with tumors enriched for the basal-like molecular subtype exhibit enhanced resistance to standard-of-care treatments and have significantly worse overall survival compared with patients with...
5.
Han X, Burrows M, Kim L, Xu J, Vostrejs W, Van Le T, et al.
Cell Rep
. 2024 Nov;
43(11):114972.
PMID: 39535921
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with abundant cancer-associated fibroblasts (CAFs) creating hallmark desmoplasia that limits oxygen and nutrient delivery. This study explores the importance of lipid homeostasis...
6.
Wasko U, Jiang J, Dalton T, Curiel-Garcia A, Edwards A, Wang Y, et al.
Nature
. 2024 Nov;
635(8040):E12.
PMID: 39533066
No abstract available.
7.
Markosyan N, Kim I, Arora C, Quinones-Ware L, Joshi N, Cheng N, et al.
JCI Insight
. 2024 Sep;
9(21).
PMID: 39298269
Tumor cell-derived prostaglandin E2 (PGE2) is a tumor cell-intrinsic factor that supports immunosuppression in the tumor microenvironment (TME) by acting on the immune cells, but the impact of PGE2 signaling...
8.
Radwan A, Eccleston J, Sabag O, Marcus H, Sussman J, Ouro A, et al.
Proc Natl Acad Sci U S A
. 2024 Sep;
121(39):e2411352121.
PMID: 39292740
A number of studies have demonstrated that it is possible to directly convert one cell type to another by factor-mediated transdifferentiation, but in the vast majority of cases, the resulting...
9.
Aguirre A, Stanger B, Maitra A
Cancer Res
. 2024 Sep;
84(18):2950-2953.
PMID: 39279379
KRAS is the most frequently altered oncogene in pancreatic ductal adenocarcinoma, in which the aberrantly activated RAS signaling pathway plays pleiotropic roles in tumor initiation and maintenance. Nearly four decades...
10.
Lu Z, Verginadis I, Kumazoe M, Castillo G, Yao Y, Guerra R, et al.
Sci Transl Med
. 2024 Aug;
16(761):eadn0904.
PMID: 39167664
Deficit of oxygen and nutrients in the tumor microenvironment (TME) triggers abnormal angiogenesis that produces dysfunctional and leaky blood vessels, which fail to adequately perfuse tumor tissues. Resulting hypoxia, exacerbation...